Skip to main content
BioCentury Innovations (formerly SciBX)
Feature Story

Cover Story: Strategy: PD-1 matchmaking

Courting combinations with PD-1

By Stephen Parmley, Senior Writer

The rush to find combinations of PD-1 inhibitors and established cancer therapies marks the end of the beginning, rather than the beginning of the end, of the search for ways to extend use of checkpoint inhibitors to the two-thirds of patients who are non-responders. The new thinking is that emerging targets in the tumor microenvironment can either turbo-boost PD-1 or re-arm the immune response, but researchers will need a streamlined strategy to select the right targets to match in different tumors.

The concept of targeting the tumor microenvironment is moving fast from the lab to the boardroom. Two weeks ago, Surface Oncology Inc. announced a $35 million series A round led by the company's seed investor, Atlas Venture. The newco was set up late last year to find immune processes beyond PD-1 that can be targeted in cancer.

Read Article | PDF

Today's Biotech & Pharma News

  • THE DISTILLERY brings you this week's most essential scientific findings in therapeutics, distilled by Innovations editors from a weekly review of more than 400 papers in 41 of the highest-impact journals in the fields of biotechnology, the life sciences and chemistry. The Distillery goes beyond the abstracts to explain the commercial relevance of featured research, including licensing status and companies working in the field, where applicable.

    This week in therapeutics includes important research findings on targets and compounds, grouped first by disease class and then alphabetically by indication.

    This week in techniques includes findings about research tools, disease models and manufacturing processes that have the potential to enable or improve all stages of drug discovery and development.

Subscribe Now
Free Trial